Articles tagged "Rejection"

2020 American Transplant Congress
Changes in Gut Microbiota and Acute Rejection after Kidney Transplantation
H. Cho¹, J. Kim², H. Kim², J. Park³, M. Kwak⁴, B. Kim⁴, D. Kim², J. Lee⁵, B. Kim⁶, H. Lee²
¹Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea, Republic of, ²Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of, ³Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Korea, Republic of, ⁴ChunLab Inc. Seoul National University, Seoul, Korea, Republic of, ⁵Department of Internal Medicine, Seoul National University Boramae Hospital, Seoul, Korea, Republic of, ⁶Department of Life Science, Multidisciplinary Genome Institute, Hallym University, Chuncheon, Korea, Republic of
*Purpose: Kidney transplantation (KT) is the best treatment for end-stage renal disease. Although rejection is a normal immune response of the body to a foreign…
2020 American Transplant Congress
Early Impact of Interleukin-6 Blockade on the Distribution of Peripheral Blood Immune Cell Subpopulations – 3-Month Results of a Phase 2 Trial Evaluating Clazakizumab in Late Antibody-Mediated Rejection
K. A. Doberer¹, G. A. Boehmig¹, M. Streitz², S. Schlickeiser², F. Bauernfeind¹, A. Spittler³, B. Jilma⁴, F. Eskandary¹, E. Chong⁵, S. Schranz⁴, K. Budde⁶, M. Dürr⁶
¹Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Charité Universitätsmedizin Berlin, Institute of Medical Immunology, Berlin, Germany, ³Center of Translational Research, Medical University of Vienna, Vienna, Austria, ⁴Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria, ⁵Vitaeris Inc., Vancouver, BC, Canada, ⁶Division of Nephrology and Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany
*Purpose: Interleukin-6 (IL-6) is considered to play a critical role within the multifacted pathophysiological process of antibody-mediated rejection (ABMR), including modulation of regulatory T cells…
2020 American Transplant Congress
Impact of Statin Intensity on the Development of Cardiac Allograft Vasculopathy
K. Goehring¹, W. Kuan¹, A. Sieg¹, K. L. Dawson¹, A. R. Kolodziej²
¹Department of Pharmacy, University of Kentucky HealthCare, Lexington, KY, ²Gill Heart and Vascular Institute, University of Kentucky HealthCare, Lexington, KY
*Purpose: This study aims to examine the efficacy of high-intensity statin therapy compared to low-intensity, moderate-intensity, or no statins at preventing cardiac allograft vasculopathy (CAV)…
2020 American Transplant Congress
A Bioinformatics Pipeline for the Identification of Crucial Factors for Transplant Rejection Based on NGS Data
J. Vetter¹, A. Heinzel², C. Aschauer², R. Reindl-Schwaighofer², K. Jelencsics², K. Hu², R. Oberbauer², S. Winkler¹, S. Schaller¹
¹Bioinformatics Research Group, University of Applied Sciences Upper Austria, Hagenberg Campus, Hagenberg im Muehlkreis, Austria, ²Department of Nephrology and Dialysis, Medical University Vienna, Vienna, Austria
*Purpose: T and B cells are crucial parts of the human immune system and play an important role in transplantation. Since the mechanisms leading to…
2020 American Transplant Congress
The State of Interventional Clinical Trials in Solid Organ Transplant: Insights from a Systematic Analysis of Clinicaltrials.gov
A. C. Swaminathan¹, J. Li¹, K. Chiswell¹, W. McManigle¹, I. O’Doherty², W. Fitzsimmons³, J. L. Todd¹, S. Tibbs⁴, S. M. Palmer¹
¹Duke Clinical Research Institute, Durham, NC, ²Critical Path Institute, Tuscan, AZ, ³Fitzsimmons LLC, Chicago, IL, ⁴Duke University, Durham, NC
*Purpose: The approach to immunosuppression after solid organ transplant has remained relatively unchanged for almost 20 years, despite the high prevalence of immunosuppression-related complications and…
2020 American Transplant Congress
Pattern of Renal Allograft Injury in Recipients with Normal Donor-Derived Cell-Free DNA
W. Xie, N. Goussous, A. Haririan, M. Weir, J. Bromberg
University of Maryland School of Medicine, Baltimore, MD
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a novel non-invasive test currently used as a biomarker for identification of transplant rejection or injury. Here, we sought…
2020 American Transplant Congress
Outcomes of Acute Allograft Rejection Treatment with R Anti-Thymocyte Globulin (r-ATG) One Year Post Kidney Transplant
M. Yaqub, A. Riaz, D. Mishler, O. Adebiyi, T. Taber, A. Sharfuddin
Indiana University School of Medicine, Indianapolis, IN
*Purpose: Acute allograft rejection is considered one of the major causes of renal allograft dysfunction. Despite maximal anti-rejection therapy grafts may not regain baseline function.…
2020 American Transplant Congress
Characterization of Non HLA Antibodies in Kidney Transplant Recipients
S. Rodriguez Ramirez¹, S. Clotet-Freixas¹, C. Mcevoy¹, M. Kotlyar², I. Jurisica², A. Chruscinski¹, A. Konvalinka³
¹Kidney Transplant, Toronto General Hospital Research Institute, Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada, ²Kidney Transplant, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Kidney Transplant, Department of Medicine, Division of Nephrology, University Health Network, Toronto, ON, Canada
*Purpose: Antibody mediated rejection (AMR) causes more than 60 percent of late graft failures in kidney transplants (KT). Although antiHLA donor specific antibodies are the…
2020 American Transplant Congress
Sirolimus Plus Tacrolimus Immunosuppression, with or without Mycophenolate Mofetil, May Improve Survival after Bronchiolitis Obliterans Syndrome in Lung Transplant Patients
M. Wijesinha, M. Terrin, B. Griffith, A. Iacono
University of Maryland School of Medicine, Baltimore, MD
*Purpose: There are very few ways to improve survival after bronchiolitis obliterans syndrome (BOS), the leading cause of death in lung transplant patients. Two long-term…
2020 American Transplant Congress
Early Prediction of Human Renal Allograft Rejection (AR) by Inflammatory Transitional B Cells
A. Cherukuri¹, A. Sharma¹, R. Mehta¹, H. Sundaram¹, A. Salama², D. Rothstein¹
¹Starzl Transplantation Institute, UPMC, Pittsburgh, PA, ²UCL, London, United Kingdom
*Purpose: Early prediction of AR within the 1st post-transplant year could identify at-risk patients for targeted therapeutic interventions to mitigate risk and improve outcomes.*Methods: In…